Muscle Memory After Treatment With Anabolic Substance Clenbuterol and Resistance Training in Humans

Not Applicable

Recruiting

• Conditions: Skeletal Muscle Physiology
• Interventions: Drug: Placebo; Drug: Clenbuterol

• Registration Number: NCT05692856
• Lead Sponsor: Morten Hostrup, PhD

Brief Summary

The purpose of the project is investigate muscle memory and underlying mechanisms in humans following resistance training and use of the anabolic substance clenbuterol.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-12-23
• Status Verified: 2023-01
• Study First Submitted QC: 2023-01-19
• Last Update Submitted: 2023-01-19
• Study First Posted: 2023-01-20
• Last Update Posted: 2023-01-20
• Study Start: 2023-02-01
• Primary Completion: 2024-12-01
• Study Completion: 2025-08-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Healthy men and women
• BMI of <26 and normal ECG and blood pressure

Exclusion Criteria

• Smoking
• Chronic disease,
• Use of prescription medication
• Pain due to current or previous musculoskeletal injury
• Resistance training more than once per week in the 12 months leading up to the intervention
• Current or previous use of prohibited anabolic substances

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Participants are randomized to daily ingestion of placebo for a period of 8 weeks, with or without supervised resistance training.
Clenbuterol	Clenbuterol	Participants are randomized to daily ingestion of clenbuterol for a period of 8 weeks, with or without supervised resistance training.

Primary Outcome Measures

Name	Time	Method
Skeletal muscle proteome	The change in the muscle proteome is assessed at baseline, 8, 24 and 32 weeks	Pathway enrichment analysis of the muscle proteome using mass-spectrometry based proteomics
Myonuclei	The change in myonuclei is assessed at baseline, 8, 24 and 32 weeks	Immunohistochemistry to determine number of myonuclei
Fiber cross-sectional area	The change in fiber cross-sectional is assessed at baseline, 8, 24 and 32 weeks	Immunohistochemistry to determine fiber cross-sectional area

Secondary Outcome Measures

Name	Time	Method
Lean mass	The change in lean mass is assessed at baseline, 8, 24 and 32 weeks	Lean mass assessed by dual X-ray absorptiometry (DXA)
Satellite cells	The change in satellite cells is assessed at baseline, 8, 24 and 32 weeks	Immunohistochemistry to determine number of satellite cells
Dynamic muscle strength	The change in 1-repetition maximum is assessed at baseline, 8, 24 and 32 weeks	1-repetition maximum
Isometric muscle strength	The change in maximal voluntary isometric contraction is assessed at baseline, 8, 24 and 32 weeks	Maximal voluntary isometric contraction of m. quadriceps
Sprint performance	The change in sprint performance is assessed at baseline, 8, 24 and 32 weeks	Work performed (W) during a sprint on a bicycle ergometer

Trial Locations

Locations (1)

August Krogh Building; 🇩🇰 Copenhagen, Denmark